Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update

Traws Pharma, Inc. (NASDAQ:TRAW) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 141,900 shares, an increase of 1,956.5% from the December 15th total of 6,900 shares. Approximately 5.2% of the shares of the company are sold short. Based on an average trading volume of 503,100 shares, the days-to-cover ratio is currently 0.3 days.

Traws Pharma Price Performance

NASDAQ:TRAW traded up $0.26 during mid-day trading on Wednesday, hitting $6.94. 46,458 shares of the stock were exchanged, compared to its average volume of 209,808. The stock’s 50-day moving average price is $6.49. The stock has a market cap of $21.00 million, a PE ratio of -0.05 and a beta of 1.13. Traws Pharma has a fifty-two week low of $4.06 and a fifty-two week high of $27.50.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.